Home : Unsafe Drugs : Vytorin : Newsfeeds

Vytorin - Newsfeeds

Merck, Schering Launch Huge Heart-Drug Test
Patients will either receive 40 milligrams of Zocor, the second-highest dose, or a dose of Vytorin that combines 40 mg of Zocor with 10 mg of Zetia. Patients will be followed for two years, and the number of heart attacks, deaths, re-hospitalizations for ...
Students Rally Together Against Legislation at State Capitol
There was a sea of white at the state Capitol as a group of more than 200 high school students and staff held a peaceful protest against anti-immigration legislation on Wednesday. Students from Carl Hayden High School and other neighboring schools marched ...
Scottsdale Healthcare Offers Free Skin Cancer Screening
SCOTTSDALE, Ariz.  – Screening for skin cancer, which can lead to early detection and better outcomes, is especially important in the Valley of the Sun. That’s why the Virginia G. Piper Cancer Center at Scottsdale Healthcare will offer a free ...
In Patients with Type 2 Diabetes and Combined Dyslipidemia, Statins Have Different Effects on Fasting Plasma Glucose
NEW ORLEANS , LA— Twelve weeks of therapy with atorvastatin 20mg significantly increased fasting plasma glucose (FPG) in patients with type 2 diabetes and combined dyslipidemia; in contrast, no significant changes were noted with pitavastatin 4mg ...
Millennium submits two VELCADE sNDAs to FDA
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced that it has submitted two supplemental new drug applications (sNDAs) for VELCADE ® (bortezomib) for Injection to the U.S. Food ...
CORRECT: UPDATE: Merck 1Q Net Soars Amid Fewer Charges; Core Results Top Views
Remicade sales rose 12% to $753 million, while sales of diabetes drug Januvia were up 45% at $739 million. Cholesterol drug Zetia had sales of $582 million, up 9%. Combined sales of antihypertension drugs Cozaar and Hyzaar dropped 46% due to generic competition.
Merck Tops on Lower Costs
Gardasil, Merck’s cervical cancer vaccine, posted sales of $214 million, down 8% year over year. Zostavax sales fell 74% to $24 million. The decline in Zostavax sales was expected due to supply issues. Meanwhile, Merck’s ProQuad, MMR II and Varivax ...
Selected first-quarter drug sales for Merck & Co.
Here are sales figures for the first quarter for Merck & Co.'s 10 top-selling drugs: PRODUCT NAME CONDITION/USE 1Q 2011 SALES 1Q 2010 SALES PERCENT CHANGE Singulair Asthma/allergies ...
Study shows immune therapy can prevent pregnancy in mammals including humans
Researchers at Weill Cornell Medical College have shown that it is possible to immunize mammals to control fertility. They say their technique could possibly be used on other mammals -- including humans -- because fertility hormones and their receptors are ...
PHIL SCHILTZ: Derailing the third rail of politics
What is the problem with making changes to Social Security, Medicare and Medicaid? They are said to be “third-rail programs.” But why? Only because those who are satisfied with the status-quo and want to perpetuate entitlement slavery are not afraid of ...
Advertising a different way to fight cholesterol - but without evidence on big outcomes
And a student came up after class waving this full-page color ad he saw in the Star Tribune newspaper. It was a Zetia drug ad. The banner promotes the drug's "different way to help lower cholesterol." But the student drew my attention to the bottom of the ...
Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710
WHITEHOUSE STATION, N.J., and VIENNA, April 11, 2011 /PRNewswire/ -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Intercell AG (VSE: ICLL) today announced that following a pre-specified interim analysis from the Phase II/III ...
Genzyme, Isis present mipomersen phase 3 study data in severe heFH at ACC meeting
Genzyme Corp., a subsidiary of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) announced today that data from two phase 3 studies of mipomersen in patients who had high cholesterol levels while on lipid ...
TABLE-Pipeline of drugs losing patent protection
BANGALORE, April 12 (Reuters) - Drugs worth more than $140 billion are expected to lose patent protection in the next five years, opening up a huge opportunity for Indian makers of generic drugs. [ID:nL3E7ET10E] The following table lists some of the major ...
More evidence ties cholesterol drug, diabetes
NEW YORK (Reuters Health) – People on a high-dose regimen of the cholesterol drug Lipitor may have a slightly increased risk of developing type 2 diabetes -- particularly if they have several of the classic diabetes risk factors, a study published Monday ...
Controlled-Release Phentermine/Topiramate Produces and Maintains Significant Weight Loss and CV Risk Reduction Over 2 Years
resulted in significant weight loss and improvements in cardiovascular risk factors in a comorbid population of overweight and obese subjects in two consecutive clinical trials (CONQUER and SEQUEL) reported on at ACC.11, the American College of Cardiology ...
Statin Drugs May Cut Risk of Kidney Trouble After Surgery
April 14, 2011 -- Statin medications , which are prescribed to lower cholesterol , may have an added benefit -- protecting the kidneys from shutting down soon after surgery, a new study shows. For reasons doctors don’t completely understand, this ...
Zetia Heart Attack
Merck and Schering-Plough have marketed both Zetia (which works in the digestive tract differently than a statin) and Vytorin —the latter is a combination of Zetia and a statin. Taken in combination with a statin, Zetia has been linked to a number of ...
Zetia Oral Side Effects
Dizziness, headache, diarrhea, back pain may occur. If any of these effects persist or worsen, notify your doctor or pharmacist promptly. Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is ...
TABLE-Pipeline of drugs losing patent protection
BANGALORE, April 12 (Reuters) - Drugs worth more than $140 billion are expected to lose patent protection in the next five years, opening up a huge opportunity for Indian makers of generic drugs. The following table lists some of the major drugs going off ...
Looking for a Vytorin lawyer in District of Columbia? Get in touch with one of our Vytorin lawyers in District of Columbia now.

Content provided by MSN. LegalView is not responsible for the accuracy of the information provided above.

Pages:   1   2   3   4   5   6   ...   Next

Need A Vytorin Attorney?

First Name Last Name Email Address State
Was Your Health Negatively Affected?

Please Describe the Injury

Your Friend's Email Address

Your Email Address

Type a Message (optional)


Looking for a Vytorin lawyer in District of Columbia? Get in touch with one of our Vytorin lawyers in District of Columbia now.

 

Close (x)

Looking for an Attorney?


Please type your question:

Close (x)

logo Find Legal Help for Your Vytorin Case - Submit Your Information Below

Do you need legal assistance with your Vytorin case?
LegalView may be able to help.


Submit your information below for a free, no-cost evaluation.

We'll submit your information to one of our partner firms.
LegalView's partners represent clients throughout the United States, for a very wide range of legal issues. Submit your information now, to see if one of LegalView's partners can help!

* Indicates Required Fields

First name *
Last name *
Email Address *
Phone Number *
()  -

State *
Legal Issue * Unsafe Drugs: Vytorin Change
Was There an Injury?
Please Describe The Injury

DISCLAIMER and STATEMENT OF NON-CONFIDENTIALITY

By submitting this form, you agree that completing the above is not intended to create an attorney-client relationship.

Disclosure

Legal WebTV Network LLC, LegalView.com, and LegalWebMedia.com are group advertising sponsored by the attorneys identified here. It is not a lawyer referral service. If you submit information on this website [more...]

Legal WebTV Network LLC, LegalView.com, and LegalWebMedia.com are group advertising sponsored by the attorneys identified here. It is not a lawyer referral service. If you submit information on this website, LegalWebMedia.com will submit your information to the law firms that pay for this group advertising and to respond to your requests for information concerning legal services in their assigned local areas. If there is no sponsoring firm in your state, your inquiry will be submitted to one of the sponsoring law firms on a predetermined, rotating basis. If the sponsoring law firm accepts your case, it will associate with licensed attorneys practicing in your state, if required; the sponsoring law firm may also contact other law firms to see if they may be able to assist.

The information provided by the LegalView.com and LegalWebMedia.com websites is for advertising and informational purposes and should not be considered as legal advice from the sponsoring attorneys. The websites contain general information and may not reflect current legal developments, verdicts, or settlements. LegalView.com contains information created by others or supplied through open forums; the sponsoring law firms are not responsible for the accuracy of this information. Any person viewing or receiving information from these websites should not act or refrain from acting on the basis of any such information without first seeking appropriate legal advice from an attorney in your area. Legal WebTV Network, LLC expressly disclaims any liability with respect to actions taken or not taken by the recipient based on any or all of the information or contents contained in these websites.

Any information sent to Legal WebTV Network LLC through this website is done using standard Web encryption techology. LegalView.com will exercise all reasonable care, within technological limits, to protect the confidentiality of any information submitted via Internet e-mail or through this website. By accessing this website, you may be seeking an attorney to represent you or legal advice. However, none of the sponsoring attorneys represent you yet.

The choice of a lawyer is an important decision and should not be based solely upon advertisements.

Any transmission of information, whether via Internet e-mail or through the website, is solely for evaluation purposes by the sponsoring law firms and their associates. The transmission of any information to any attorney sponsoring advertising on LegalView.com or LegalWebMedia.com does not create an attorney-client relationship between the sender and any recipient. An attorney-client relationship can only be created by a written, signed-fee agreement entered into with an attorney. The sponsoring attorneys will treat your information as a confidential communication for the purpose of obtaining legal services or legal advice.

For more information about the sponsoring law firms, please click here.
This form is secure and encrypted. More information about secure forms and your privacy here.